Article
A phase I pharmacologic and pharmacogenetic trial of sequential 24-hour infusion of irinotecan followed by leucovorin and a 48-hour infusion of fluorouracil in adult patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jun 2005
Wright Maurice A, Morrison Geraldine, Lin Pengxin, Leonard Gregory D, Nguyen Dat, Guo Xaiodu, Szabo Eva, Hopkins Jon L, Leguizamo Jorge P, Harold Nancy, Fioravanti Suzanne, Schuler Barbara, Monahan Brian P, Saif M Wasif, Quinn Mary G, Pang Janet, Grem Jean L
Abstract excerpt
PURPOSE: In preclinical studies, sequential exposure to irinotecan (CPT-11) then fluorouracil (5-FU) is superior to concurrent exposure or the reverse sequence; a 24-hour infusion of CPT-11 may be better tolerated than shorter infusions. EXPERIMENTAL DESIGN: CPT-11 was first given at four levels (70-140 mg/m(2)/24 hours), followed by leucovorin 500 mg/m(2)/0.5 hours and 5-FU 2,000 mg/m(2)/48 hours on days 1 and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.